Results 221 to 230 of about 462,118 (388)

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

<b>IMMUNOCYTOCHEMICAL LOCALIZATION OF ANGIOTENSIN CONVERTING ENZYME AT THE ULTRASTRUCTURAL LEVEL IN THE HUMAN LUNG AND </b><b>KIDNEY </b>

, 1982
Yasuharu Takada, Kunio Hiwada, M Unno, Tatsuo Kokubo   +3 more
openalex   +2 more sources

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. [PDF]

, 1981
D. B. Brunner, G Desponds, Jérôme Biollaz, I Keller, F Ferber, Haralambos Gavras, Brunner Hr, JL Schelling   +7 more
openalex   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Angiotensin-converting enzyme genotypes and sarcoidosis: Correlation with susceptibility, progression and treatment response. [PDF]

Sarcoidosis Vasc Diffuse Lung Dis
Møller J, Hilberg O, Nissen PH, Møller HJ, Bendstrup KE.   +4 more
europepmc   +1 more source

Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT? [PDF]

, 2001
McMurray, John J.V.
core   +1 more source

Isolation and characterization of I5B2, a new phosphorus containing inhibitor of angiotensin I converting enzyme produced by Actinomadura sp.

, 1984
Yasuji Kido, Toshinari Hamakado, MASAMI ANNO, Eiji Miyagawa, Yoshinobu Motoki, Tateaki Wakamiya, Tetsuo Shiba   +6 more
openalex   +2 more sources

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Angiotensin-converting enzyme inhibitors for aortic stenosis: a drug-target Mendelian randomization study. [PDF]

Int J Cardiol Heart Vasc
Ciofani JL, Han D, Woolf B, Gill D, Allahwala UK, Bhindi R.   +5 more
europepmc   +1 more source

Zinc Deficiency in Rats and Angiotensin-Converting Enzyme Activity: Comparative Effects on Lung and Testis

, 1988
Philip G. Reeves, Boyd L. O’Dell
openalex   +1 more source